Subscribe
PCV21 improved all outcomes for individuals aged 19 to 64 years, including invasive pneumococcal disease, postmeningitis sequelae, and nonbacteremic pneumococcal pneumonia.
Gaps Between Expectations and Effects of Long COVID Affect Trust in Vaccines
Vaccination of 3 Or More Doses Reduces Incidence of COVID-19 Symptoms for Young Adults
Vaccine Hesitancy Rises, Highlighting a Crucial Role for Pharmacists
Vaccine Messaging for Teens Should Tailor to Personal Perspectives